Moleculin Biotech (MBRX) Expected to Announce Quarterly Earnings on Friday

Posted by Defense World Staff on Nov 7th, 2025

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) is anticipated to issue its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:00 PM ET.

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts expect Moleculin Biotech to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Moleculin Biotech Price Performance

MBRX opened at $0.46 on Friday. The company has a fifty day moving average price of $0.45 and a 200-day moving average price of $0.62. The firm has a market capitalization of $22.60 million, a P/E ratio of -0.14 and a beta of 1.57. Moleculin Biotech has a one year low of $0.25 and a one year high of $3.65.

Analyst Ratings Changes

Several analysts have weighed in on MBRX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Moleculin Biotech in a research note on Wednesday, September 10th. Finally, Wall Street Zen lowered shares of Moleculin Biotech to a “strong sell” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Moleculin Biotech presently has a consensus rating of “Hold” and an average price target of $4.00.

Read Our Latest Stock Report on Moleculin Biotech

Moleculin Biotech Company Profile

(Get Free Report)

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.